Brief: Schrödinger Announces FDA Clearance Of Investigational New Drug Application For Sgr-1505, A Malt1 Inhibitor

Schrodinger

28/06/2022 12:05

June 28 (Reuters) - Schrodinger Inc  SDGR.O :
    * SCHRÖDINGER ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW
DRUG
APPLICATION FOR SGR-1505, A MALT1 INHIBITOR
    * SCHRODINGER INC - PHASE 1 CLINICAL TRIAL IN PATIENTS WITH
ADVANCED B-CELL MALIGNANCIES EXPECTED TO BEGIN IN SECOND HALF OF
2022 FOR SGR-1505

Source text for Eikon:  ID:nBw8R6B5va 
Further company coverage:  SDGR.O 

 ((Reuters.Briefs@thomsonreuters.com;))